Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2024 / Feb / Reading Between the… Diagnoses
Omics Metabolomics & Lipidomics Clinical Mass Spectrometry

Reading Between the… Diagnoses

Metabolomic profiling reveals 17 possible diagnostic markers for mood disorders

By Markella Loi 02/29/2024 1 min read

Share

Patients with bipolar disorder are often misdiagnosed with major depressive disorder (MDD) because of overlapping symptoms, as well as the subjective nature of psychiatric evaluation of patient self-reported information. Indeed, one third of bipolar patients remain misdiagnosed for over seven years (1). 

To address the issue, a research team from the University of Cambridge, UK, analyzed dried blood spots from individuals suffering from current depressive symptoms (2).

“We initially attempted to identify biomarkers of these conditions using proteomic profiling based on mass spectrometry; unfortunately, the signal was not strong enough,” says Sabine Bahn, Head of the Cambridge Centre for Neuropsychiatric Research and corresponding author. “We then turned to metabolomic profiling; we expected metabolites to be more stable in dried blood spots and provide a better signal than proteins, which they indeed did.” 

First, the samples were analyzed using a targeted mass spectrometry-based platform to measure the levels of 630 circulating metabolites. Next, the participants underwent a WHO validated diagnostic interview to determine whether they had BD so that correlations could be made with biomarker levels.

“We discovered a panel of 17 biomarkers that correctly detected 53 percent of patients with BD and 76 percent of patients with MDD in a group of 241 patients. These findings were then validated in a separate group of 30 patients,” says Jakub Tomasik, Senior Research Associate at the Cambridge Centre for Neuropsychiatric Research and principal author of the paper. “The biomarkers were especially useful in patients whose diagnoses based on self-reported symptoms were uncertain and those who underreported their symptoms.”

The researchers are planning a validation study to test the performance of the biomarker panel in a new group of patients with fresh dried blood samples.

“A blood biomarker test could provide a faster and more objective way to diagnose mood disorders,” says Bahn. “As such, it could substantially improve the diagnostic process, reducing the workload on physicians and helping select the right treatment early in the process.” 

Tomasik adds, “It would not only result in better outcomes in patients, but also contribute to more informed understanding of psychiatric disease and help reduce the stigma associated with psychiatric conditions.”

Image Credit: Cambridge Centre for Neuropsychiatric Research

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. RMA Hirschfeld et al., J Clin Psychiatry, 64, 2, (2003). DOI: 10.4088/JCP.v64n0209. 
  2. J Tomasik et al., JAMA Psychiatry , (2023). DOI: 10.1001/jamapsychiatry.2023.4096. 

About the Author(s)

Markella Loi

Associate Editor, The Analytical Scientist

More Articles by Markella Loi

False

Advertisement

Recommended

False

Related Content

The Analytical Scientist Innovation Awards 2024: #7
Omics
The Analytical Scientist Innovation Awards 2024: #7

December 2, 2024

4 min read

Frank Steemers, co-founder and CSO of Scale Biosciences, tells us the story of ScalePlex – the 7th ranked innovation on this year’s Awards

The Analytical Scientist Innovation Awards 2024: #4
Omics
The Analytical Scientist Innovation Awards 2024: #4

December 5, 2024

6 min read

Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

Let Me See That Brain
Omics
Let Me See That Brain

December 9, 2024

1 min read

TRISCO sets a new standard for 3D RNA imaging, delivering high-resolution and uniform images to offer insights into brain function and anatomy

The Analytical Scientist Innovation Awards 2024
Omics
The Analytical Scientist Innovation Awards 2024

December 11, 2024

10 min read

Meet the products – and the experts – defining analytical innovation in 2024

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.